Model-Informed Confidence in Oncology Dose Selection
Discover an oncology-focused company that gained confidence in their dose selection for an AML trial…
CertaraAugust 9, 2024
Go beyond basic validation: Achieve submission-ready datasets with Pinnacle 21 Enterprise
Explore how Pinnacle 21 Enterprise simplifies dataset validation, enhances compliance, and prepares you for regulatory…
CertaraAugust 9, 2024
Pinnacle 21 Non-CRF Data
Learn how Pinnacle 21 Non-CRF Data Exchange streamlines vendor data with collaborative spec design, automated…
CertaraAugust 9, 2024
Digital Payer Portals for Enhanced Value Communication
JTVCdGVhbV9qdW1wX2xpc3QlNUQ=August 9, 2024 The trend of using digital tools for communication and information sharing in…
CertaraAugust 9, 2024
Summarize This! GPT Prompts for Regulatory Writers
With the advent of GPTs, regulatory writers face an opportunity and a challenge. The opportunity?…
CertaraAugust 8, 2024
Reactor in Large Library Workflows
Explore the evolution of billion-scale chemical libraries, driven by advancements in cloud computing, AI/ML, and…
CertaraAugust 8, 2024
Certara’s MIDD Oncology Capabilities
Improve Oncology Study Decisions with Certara's MIDD Team Transcript: The pace of oncology drug…
CertaraAugust 7, 2024
A quick guide to implementing a Clinical Metadata Repository
Read our free guide to learn the three-step best practice process to implementing a Clinical…
CertaraAugust 7, 2024
Certara Reports Second Quarter 2024 Financial Results
Reiterates Full Year 2024 Financial Guidance RADNOR, PA — August 6, 2024-- Certara, Inc. (Nasdaq: CERT),…
CertaraAugust 6, 2024
